Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.
about
Cough: an unmet clinical need.Influence of baclofen on laryngeal and spinal motor drive during cough in the anesthetized catTranslational approach to develop novel medications on alcohol addiction: focus on neuropeptides.Pre-clinical studies in cough research: role of Transient Receptor Potential (TRP) channelsNociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.Targeting peripheral afferent nerve terminals for cough and dyspnea.Where are the new cough treatments: a debriefing of recent clinical proof-of-concept trials with the NOP agonist SCH 486757.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure.In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.Effects of SCH 486757, a nociceptin-1 receptor agonist, on fertility and reproductive hormone levels in female CRL:CD®[SD] rats.The nociceptin receptor inhibits axonal regeneration and recovery from spinal cord injury.Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic
P2860
Q24604012-B5C5FC4A-5829-4464-B2BA-890AF3ED6D69Q37074807-026D2B7D-2492-487F-B41A-E5B865EB331FQ37076193-77DE67A9-3C1E-42BF-8D90-869F4EB0E86EQ37148090-0EA05E67-0903-4E7D-86AE-402A082C677EQ37211503-6AA1FD0E-9224-4FCF-9B49-2631DFADC033Q37894474-363D1B45-EEE8-4C3C-BB17-4C5EBB0F6F11Q37901296-6F31C951-F0D9-4976-BAAE-9F987C193F6EQ38217456-9E68DA03-0DD0-4450-80D0-7093EA02171BQ42709118-C03E652C-7884-45B1-97E0-29F898E3098FQ45998228-D4A4CD66-E13D-443B-86AD-69A49D21541DQ51412972-6EEAA05B-04C0-47B1-AEEE-5A0A21573843Q52609070-3201BCA5-5806-4F48-BC99-2295F03E75B5Q58545262-9D78BC9C-2B61-4EF1-9FEE-0FE00974F281
P2860
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@ast
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@en
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757
@nl
type
label
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@ast
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@en
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757
@nl
prefLabel
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@ast
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@en
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757
@nl
P2093
P2860
P1476
Pharmacological profile of the ...... n-3-Ol) in preclinical models.
@en
P2093
Ahmad B Fawzi
April Smith-Torhan
Christine H Erickson
Deen B Tulshian
Donald C Bolser
Geoffrey B Varty
Ginny D Ho
Jennifer C Zimmer
John A Hey
P2860
P304
P356
10.1016/J.EJPHAR.2009.12.003
P407
P577
2009-12-16T00:00:00Z